Skip to main content
OpenTrials

Clinical trial condition

Myeloproliferative Disorders

Explore clinical trials studying Myeloproliferative Disorders. Study availability and eligibility vary by location and protocol.

1,108 public trials 143 recruiting studies
Refine in advanced search Browse all conditions

Myeloproliferative Disorders trial results

Completed

Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)

NCT01243944

Conditions
Bone Marrow Diseases, Bone Marrow Neoplasms, Hematologic Diseases, +6 more
Locations
  • Birmingham, Alabama, United States
  • Scottsdale, Arizona, United States
  • Pomona, California, United States
  • Sacramento, California, United States
View all 102 locations
View Trial Details
Completed

Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia

NCT01031368

Conditions
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), +31 more
Locations
  • Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Seattle, Washington, United States
View Trial Details
Completed

Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis

NCT01423058

Conditions
Bone Marrow Diseases, Hematologic Diseases, Hemic and Lymphatic Diseases, +4 more
Locations
  • Mayo Clinic Scottsdale, Arizona, United States
  • Mayo Clinic Jacksonville, Florida, United States
  • MD Anderson Cancer Center, The University of Texas Houston, Texas, United States
  • Huntsman Cancer Institute at the University of Utah Salt Lake City, Utah, United States
View Trial Details
Completed

Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)

NCT01236638

Conditions
Bone Marrow Diseases, Hematologic Diseases, Hemic and Lymphatic Diseases, +4 more
Locations
  • Stanford Cancer Center Stanford, California, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Mayo Clinic Rochester, Minnesota, United States
  • The Royal Melbourne Hospital Parkville, Victoria, Australia
View Trial Details
Completed

Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)

NCT00935987

Conditions
Bone Marrow Diseases, Hematologic Diseases, Hemic and Lymphatic Diseases, +4 more
Locations
  • Stanford Cancer Center Stanford, California, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Mayo Clinic Rochester, Minnesota, United States
  • The Royal Melbourne Hospital Parkville, Victoria, Australia
View Trial Details
Completed

Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)

NCT02208037

Conditions
Acute Leukemia, Anemia, Anemia, Refractory, +35 more
Locations
  • City of Hope National Medical Center Duarte, California, United States
  • Stanford Hospital and Clinics Stanford, California, United States
  • University of Florida College of Medicine (Shands) Gainesville, Florida, United States
  • H. Lee Moffitt Cancer Center Tampa, Florida, United States
View all 30 locations
View Trial Details

Related conditions